<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0509245865
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Prestoprix Plus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMLODIPINE BESILATE,PERINDOPRIL ARGININE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        75.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prestoprix&reg; Plus is prescribed for treatment of high blood pressure (hypertension) and/or treatment of stable coronary artery disease (a condition where the blood supply to the heart is reduced or blocked).</p><p>Patients already taking perindopril and amlodipine from separate tablets may instead receive one tablet of Prestoprix&reg; Plus which contains both ingredients.</p><p>Prestoprix&reg; Plus is a combination of two active ingredients, perindopril and amlodipine. Perindopril is an ACE (angiotensin converting enzyme) inhibitor. Amlodipine is a calcium antagonist (which belongs to a class of medicines called dihydropyridines). Together they work to widen and relax the blood vessels so that blood passes through them more easily and makes it easier for your heart to maintain a good blood flow.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Prestoprix&reg; Plus:</p><p>If you are allergic to perindopril or any other ACE inhibitor, or to amlodipine or any other calcium antagonists, or any of the other ingredients of this medicine.</p><p>If you are more than 3 months pregnant (It is also better to avoid Prestoprix&reg; Plus in early pregnancy).</p><p>If you have experienced symptoms such as wheezing, swelling of the face, tongue or throat, intense itching or severe skin rashes with previous ACE inhibitor treatment or if you or a member of your family have had these symptoms in any other circumstances (a condition called angioedema).</p><p>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).</p><p>If you have severe low blood pressure (hypotension).</p><p>If you suffer from heart failure after a heart attack.</p><p>If you are having dialysis or any other type of blood filtration. Depending on the machine that is used, Prestoprix&reg; Plus may not be suitable for you.</p><p>If you have kidney problems where the blood supply to your kidneys is reduced (renal artery stenosis).</p><p>If you have taken or are currently taking sacubitril/valsartan, a medicine for heart failure, as the risk of angioedema (rapid swelling under the skin in an area as the throat) is increased.</p><p>&nbsp;</p><p>Warning and precautions</p><p>If you have any of the following please talk to your doctor, pharmacist or nurse before taking Prestoprix&reg; Plus:</p><p>Hypertrophic cardiomyopathy (cardiac muscle disease) or renal artery stenosis (narrowing of the artery supplies the kidney with blood).</p><p>If you have heart failure.</p><p>If you have severe increase in blood pressure (hypertensive crisis).</p><p>If you have any other heart problems.</p><p>If you have liver problems.</p><p>If you have kidney problems or if you are receiving dialysis.</p><p>If you have abnormally increased levels of a hormone called aldosterone in your blood (primary aldosteronism).</p><p>If you suffer from a collagen vascular disease (disease of the connective tissue) such as systemic lupus erythematosus or scleroderma.</p><p>If you have diabetes.</p><p>If you are on a salt restricted diet or use salt substitutes which contain potassium (a well-balanced potassium blood level is essential).</p><p>If you are elderly and your dose needs to be increased.</p><p>If you are taking any of the following medicines used to treat high blood pressure:</p><p>&nbsp;</p><p>- An &ldquo;angiotensin II receptor blocker&rdquo; (ARBs) (also known as sartans- for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>- Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>If you are taking any of the following medicines, the risk of angioedema is increased:</p><p>&nbsp;</p><p>- Racecadotril (used to treat diarrhoea).</p><p>- Sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors (used to avoid rejection of transplanted organs and for cancer).</p><p>- Sacubitril (available as fixed-dose combination with valsartan), used to treat long-term heart failure.</p><p>- Linagliptin, saxagliptin, sitagliptin, vildagliptin and other drugs belonging to the class of the also called gliptins (used to treat diabetes).</p><p>If you are of black origin since you may have a higher risk of angioedema and this medicine may be less effective in lowering your blood pressure than in non-black patients.</p><p>&nbsp;</p><p><strong><u>Angioedema</u></strong></p><p>Angioedema (a severe allergic reaction with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing) has been reported in patients treated with ACE inhibitors, including perindopril Arginine /amlodipine. This may occur at any time during treatment. If you develop such symptoms, you should stop taking Prestoprix&reg; Plus and see a doctor immediately.</p><p>You must tell your doctor if you think you are (or might become) pregnant.</p><p>Prestoprix&reg; Plus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p>When you are taking Prestoprix&reg; Plus, you should also inform your doctor or the medical staff:</p><p>If you are going to have a general anesthetic and/or major surgery.</p><p>If you have recently suffered from diarrhea or vomiting (being sick).</p><p>If you are undergo LDL apheresis (the removal of cholesterol from your blood by a machine).</p><p>If you are going to have desensitisation treatment to reduce the effects of an allergy to bee or wasp stings.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Prestoprix&reg; Plus is not recommended for use in children and adolescents.</p><p>Other medicines and Prestoprix&reg; Plus</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>You should avoid Prestoprix&reg; Plus with:</p><p>Lithium (used to treat mania or depression).</p><p>Estramustine (used in cancer therapy).</p><p>Potassium-sparing diuretics (triamterene, amiloride), potassium supplements or potassium-containing salt substitutes, other drugs which can increase potassium in your body (such as heparin, a medicine used to thin blood to prevent clots; trimethoprim and co-trimoxazole also known as trimethoprim/sulfamethoxazole for infections caused by bacteria).</p><p>Potassium-sparing dugs used in the treatment of heart failure: eplerenone and spironolactone at doses between 12.5 mg and 50 mg per day.</p><p>&nbsp;</p><p>Treatment with Prestoprix&reg; Plus can be affected by other medicines. Your doctor may need to change your dose and/or to take other precautions. Make sure to tell your doctor if you are taking any of the following medicines as special care may be required:</p><p>Other medicines for high blood pressure, including angiotensin II receptor blockers (ARB), aliskiren or diuretics (medicines which increase the amount of urine produced by the kidneys).</p><p>Medicines, which are most often used to treat diarrhea (racecadotril) or avoid rejection of transplanted organs (sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors).</p><p>Sacubitril/valsartan (used to treat long-term heart failure).</p><p>Non-steroidal anti-inflammatory drugs (e.g. ibuprofen) for pain relief or high dose acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting.</p><p>Medicines to treat diabetes (such as insulin).</p><p>Medicines to treat mental disorders such as depression, anxiety, schizophrenia etc. (e.g. tricyclic antidepressants, antipsychotics, imipramine-like antidepressants, neuroleptics).</p><p>Immunosuppressants (medicines which reduce the defence mechanism of the body) used for the treatment of auto-immune disorders or following transplant surgery (e.g. ciclosporin, tacrolimus).</p><p>Trimethoprim and Co-trimoxazole (for the treatment of infections).</p><p>Allopurinol (for the treatment of gout).</p><p>Procainamide (for the treatment of an irregular heart beat).</p><p>Vasodilators including nitrates (products that widen the blood vessels).</p><p>Ephedrine, noradrenaline or adrenaline (medicines used to treat low blood pressure, shock or asthma).</p><p>Baclofen or dantrolene (infusion) both used to treat muscle stiffness in diseases such as multiple sclerosis; dantrolene is also used to treat malignant hyperthermia during anesthesia (symptoms including very high fever and muscle stiffness).</p><p>Some antibiotics such as rifampicin, erythromycin, clarithromycin (for infection caused by bacteria).</p><p><em>Hypericum perforatum </em>(St John&rsquo;s wort, an herbal medicine used to treat depression).</p><p>Simvastatin (cholesterol lowering medicine).</p><p>Antiepileptic agent such as carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone.</p><p>Itraconazole, ketoconazole (medicines used for treatment of fungal infections).</p><p>Alpha-blockers used for treatment of enlarged prostate such as prazosin, alfuzosin, doxazosin, tamsulosin, terazosin.</p><p>Amifostine (used to prevent or reduce side effects caused by other medicines or radiation therapy that are used to treat cancer).</p><p>Corticosteroids (used to treat various conditions including severe asthma and rheumatoid arthritis).</p><p>Gold salts, especially with intravenous administration (used to treat symptoms of rheumatoid arthritis).</p><p>Ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV).</p><p>&nbsp;</p><p>Prestoprix&reg; Plus with food and drink</p><p>Prestoprix&reg; Plus should be taken before a meal.</p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking Prestoprix&reg; Plus. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Prestoprix&reg; Plus.</p><p>Pregnancy and breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Pregnancy</p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Prestoprix&reg; Plus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Prestoprix&reg; Plus. Prestoprix&reg; Plus is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>Breast-feeding</p><p>Amlodipine has been shown to pass into breast milk in small amounts. Tell your doctor if you are breast-feeding or about to start breast-feeding. Prestoprix&reg; Plus is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>Driving and using machines</p><p>Prestoprix&reg; Plus may affect your ability to drive or use machines. If the tablets make you feel sick, dizzy, weak or tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p><p>Prestoprix&reg; Plus contains lactose</p><p>Prestoprix&reg; Plus contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Swallow your tablet with a glass of water, preferably at the same time each day, in the morning, before a meal. Your doctor will decide on the correct dose for you. This will normally be one tablet per day.</p><p>Prestoprix&reg; Plus will usually be prescribed for patients already taking perindopril and amlodipine from separate tablets.</p><p>Use in children and adolescents</p><p>Use in children and adolescents is not recommended.</p><p>If you take more Prestoprix&reg; Plus than you should</p><p>If you take too many tablets, contact your nearest accident and emergency department or tell your doctor immediately. The most likely effect in case of overdose is low blood pressure which can make you feel dizzy or faint. If this happens, lying down with your legs raised can help.</p><p>Excess fluid may accumulate in your lungs (pulmonary oedema) causing shortness of breath that may develop up to 24 - 48 hours after intake.</p><p>If you forget to take Prestoprix&reg; Plus</p><p>It is important to take your medicine every day as regular treatment works better. However, if you forget to take a dose of Prestoprix&reg; Plus, take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Prestoprix&reg; Plus</p><p>As the treatment with Prestoprix&reg; Plus is usually life-long, you should discuss with your doctor before you stop taking your tablets.</p><p>If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Prestoprix&reg; Plus can cause side effects, although not everybody gets them.</p><p>If you experience any of the following, stop taking the medicinal product at once and tell your doctor immediately:</p><p>Sudden wheeziness, chest pain, shortness of breath, or difficulty in breathing.</p><p>Swelling of eyelids, face or lips.</p><p>Swelling of the tongue and throat, which causes great difficulty breathing.</p><p>Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, Toxic Epidermal Necrolysis) or other allergic reactions.</p><p>Severe dizziness or fainting.</p><p>Heart attack, unusual fast or abnormal heart beat, or chest pain.</p><p>Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell.</p><p>&nbsp;</p><p>The following common side effects have been reported. If any of these cause you problems or if they last for more than one week, you should contact your doctor.</p><p>Very common side effect (may affect more than 1 in 10 people):</p><p>Oedema (fluid retention).</p><p>Common side effect (may affect up to 1 in 10 people):</p><p>Headache, dizziness, sleepiness (especially at the beginning of treatment), vertigo, numbness or tingling sensation in your limbs, vision disturbances (including double vision), tinnitus (sensation of noises in the ears), palpitations (awareness of your heartbeat), flushing, light-headedness due to low blood pressure, cough, shortness of breath, nausea (feeling sick), vomiting (being sick), abdominal pain, taste disturbances, dyspepsia or difficulty of digestion, change of bowel habit, diarrhea, constipation, allergic reactions (such as skin rashes, itching), muscle cramps, tiredness, weakness, ankle swelling (edema peripheral).</p><p>Other side effects that have been reported include the following list. If any of these get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>Uncommon side effect (may affect up to 1 in 100 people):</p><p>Mood swings, anxiety, depression, sleeplessness, sleep disturbances, trembling, fainting, loss of pain sensation, irregular heart beat, rhinitis (blocked up or runny nose), hair loss, red patches on skin, skin discoloration, back pain, arthralgia (joint pain), myalgia (muscle pain), chest pain, disorder in passing urine, increased need to urinate at night, increased number of times of passing urine, pain, feeling unwell, bronchospasm (tightening of the chest, wheezing and shortness of breath), dry mouth, angioedema (symptoms such as wheezing, swelling of the face or tongue), formation of blister clusters over the skin, kidney problems, impotence, increased sweating, an excess of eosinophils (a type of white blood cells), discomfort or enlargement of the breasts in men, weight increase or decrease, tachycardia, vasculitis (inflammation of blood vessels), photosensitivity reactions (increased sensitivity of the skin to sun), fever, fall, change in laboratory parameters: high blood level of potassium reversible on discontinuation, low level of sodium, hypoglycaemia (very low blood sugar level) in case of diabetic patients, increased blood urea, and increased blood creatinine.</p><p>Rare side effect (may affect up to 1 in 1000 people):</p><p>Acute renal failure, symptoms of a condition called SIADH (inappropriate antidiuretic hormone secretion): dark urine, feeling sick (nausea) or being sick (vomiting), muscle cramps, confusion and seizures, decreased or absent urine output, psoriasis worsening, changes in laboratory parameters: Increased level of liver enzymes, high level of serum bilirubin.</p><p>Very rare side effect (may affect up to 1 in 10,000 people):</p><p>Cardiovascular disorders (angina, heart attack and stroke), eosinophilic pneumonia (a rare type of pneumonia), swelling of eyelids, face or lips, swelling of the tongue and throat, which causes great difficulty in breathing, severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome), erythema multiforme (a skin rash which often starts with red itchy patches on your face, arms or legs), sensitivity to light, change in blood values such as lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets, disorders of the blood, inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell, abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests, abdominal bloating (gastritis), disorder of the nerves which can cause weakness, tingling or numbness, increased muscle tension, swelling of the gums, excess sugar in blood (hyperglycaemia).</p><p>Frequency not known (cannot be estimated from available data):</p><p>Trembling, rigid posture, mask-like face, slow movements and shuffling, unbalanced walk, discolouration, numbness and pain in fingers or toes (Raynaud&rsquo;s phenomenon).</p><p>If you have these symptoms contact your doctor as soon as possible.</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use Prestoprix&reg; Plus after the expiry date (EXP) which is stated on the Label and the carton.</p><p>The expiry date refers to the last day of that month.</p><p>Prestoprix&reg; Plus Tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Perindopril Arginine and Amlodipine (Besilate).</p><p>The other ingredients are Microcrystalline cellulose, sodium starch glycolate (Type A), colloidal anhydrous silica, magnesium stearate, lactose monohydrate spray dried, lactose monohydrate agglomerated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Prestoprix® Plus 5/5 mg: White to off white oval biconvex beveled edge tablet engraved with C22 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use.
Pack size: 30 Tablets/HDPE Bottle.
Prestoprix® Plus 10/5 mg: White to off white triangle biconvex beveled edge tablet engraved with C27 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use. 
Pack size: 30 Tablets/HDPE Bottle.
Prestoprix® Plus 10/10 mg: White to off white round biconvex beveled edge tablet engraved with C32 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use. 
Pack size: 30 Tablets/HDPE Bottle.
To report any side effect (s):
•Saudi Arabia:
The National Pharmacovigilance Center (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
•Other GCC States:
Please contact the relevant competent authority.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Med City Pharma-KSA.</p><p>Tel: 00966920003288</p><p>Fax: 00966126358138</p><p>Mobile: 00966555786968</p><p>P.O .Box: 42512 - Jeddah 21551</p><p>E-mail: MD.admin@Axantia.com</p><p>This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يتم وصف <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong> لعلاج ارتفاع ضغط الدم و/أو علاج مرض الشريان التاجي المستقر (حالة يكون فيها تزويد الدم إلى القلب منخفض أو محصور).</p><p dir="RTL">المرضى الذين يتناولون بيريندوبريل و أملوديبين باستعمال أقراص منفصلة، قد يتناولون بدلا من ذلك قرص واحد من <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong> </strong>الذي يحتوي على كلا المادتين.</p><p dir="RTL"><strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong> هو مركب من مادتين فعالتين، بيريندوبريل و أملوديبين.</p><p dir="RTL">ينتمي بيريندوبريل إلى مجموعة مثبطات الإنزيم المحول للأنجيوتنسن. ينتمي أملوديبين إلى مجموعة مضادات الكالسيوم (التي تنتمي إلى مجموعة من الأدوية تسمى البيريدين ثنائي الهيدروجين). تعملان معا لتوسيع و إرخاء الأوعية الدموية مما يؤدي إلى مرور الدم خلالها بسهولة أكبر و يسهل الحفاظ على تدفق جيد للدم إلى القلب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong> <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس لبيريندوبريل، أو لأي من مثبطات الإنزيم المحول للأنجيوتنسن الأخرى، أو لأملوديبين أو لأي من مضادات الكالسيوم الأخرى، أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا كنت حاملا لمدة تزيد عن ثلاثة أشهر (يفضل أيضا تجنب <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong><strong> </strong>في المرحلة المبكرة من الحمل).</p><p dir="RTL">إذا عانيت من أعراض مثل أزيز تنفسي، تورم الوجه، اللسان أو الحلق، حكة شديدة أو طفح جلدي حاد عند العلاج في السابق باستعمال أحد مثبطات الإنزيم المحول للأنجيوتنسن أو إذا عانيت أنت أو أحد أفراد عائلتك سابقا من هذه الأعراض في أي حالات أخرى (حالة تعرف بالوذمة الوعائية).</p><p dir="RTL">إذا كنت تعاني من داء السكري أو قصور وظيفة الكلى و كنت تخضع للعلاج باستعمال دواء خافض لضغط الدم يحتوي على الأليسكرين.</p><p dir="RTL">إذا كنت تعاني من تضيق صمام القلب الأبهري (تضيق أبهري) أو صدمة قلبية (حالة يكون فيها القلب غير قادر على تزويد الجسم بكمية كافية من الدم).</p><p dir="RTL">إذا كنت تعاني من انخفاض حاد في ضغط الدم.</p><p dir="RTL">إذا كنت تعاني من قصور وظيفة عضلة القلب بعد الإصابة بنوبة قلبية.</p><p dir="RTL">إذا كنت تخضع للديلزة الدموية أو أي نوع آخر لتنقية الدم. اعتمادا على الجهاز المستعمل، قد يكون <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong><sup>&nbsp; </sup></strong>غير مناسب لك.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى والتي ينخفض فيها تدفق الدم إلى الكلى (تضيق الشريان الكلوي).</p><p dir="RTL">إذا تناولت أو كنت تتناول حاليا دواء ساكوبيتريل/ڤالسارتان، وهو دواء يستعمل لعلاج قصور وظيفة عضلة القلب، حيث يزداد خطر الإصابة بالوذمة الوعائية (تورم سريع تحت الجلد في منطقة ما مثل الحلق).</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المحاذير</strong></p><p dir="RTL">إذا كنت تعاني من أي مما يلي الرجاء التحدث مع طبيبك، الصيدلي أو الممرض قبل تناول <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong>:</p><p dir="RTL">إذا كنت تعاني من اعتلال قلبي تضخمي (مرض في عضلة القلب) أو تضيق الشريان الكلوي (تضيق الشريان الذي يزود الكلى بالدم).</p><p dir="RTL">إذا كنت تعاني من قصور وظيفة عضلة القلب.</p><p dir="RTL">إذا كنت تعاني من ارتفاع حاد في ضغط الدم.</p><p dir="RTL">إذا كنت تعاني من أي مشاكل أخرى في القلب.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى أو إذا كنت تخضع للديلزة الدموية.</p><p dir="RTL">إذا كنت تعاني من ارتفاع غير طبيعي في مستويات هرمون يسمى ألدوستيرون في الدم (ألدوستيرونية أولية).</p><p dir="RTL">إذا كنت تعاني من مرض الكولاجين الوعائي (مرض في النسيج الضام) مثل ذأب حمامي جهازي أو تصلب الجلد.</p><p dir="RTL">إذا كنت تعاني من&nbsp; داء السكري.</p><p dir="RTL">إذا كنت تتبع نظام غذائي تكون فيه كمية الملح محدودة أو تستعمل بدائل الملح التي تحتوي على البوتاسيوم (يجب أن يكون مستوى البوتاسيوم في الدم متوازن).</p><p dir="RTL">إذا كنت من كبار السن و هناك حاجة لزيادة جرعتك.</p><p dir="RTL">إذا كنت تتناول أي من الأدوية التالية التي تستعمل لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">- أحد &ldquo;حاصرات مستقبلات أنجيوتينسن II&rdquo; (تعرف أيضا بالسارتان - على سبيل المثال ڤالسارتان، تيلميسارتان، إربيسارتان)، خصوصا إذا كنت تعاني من مشاكل في الكلى مرتبطة بداء السكري.</p><p dir="RTL">- أليسيكرين.</p><p dir="RTL">قد يقوم طبيبك بالتأكد من وظائف الكلى، ضغط الدم، و كمية الكهرليات (مثل، البوتاسيوم) في الدم على فترات منتظمة.</p><p dir="RTL">قد يزداد خطر الإصابة بالوذمة الوعائية، إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">- راسيكادوتريل (يستعمل لعلاج الإسهال).</p><p dir="RTL">- سيروليموس، إڤيروليموس، تيمسيروليموس و أدوية أخرى تنتمي إلى مجموعة تعرف بمثبطات هدف الثدييات من الراباميسين (تستعمل لتجنب رفض العضو المزروع و لعلاج السرطان).</p><p dir="RTL">&nbsp;- ساكوبيتريل (متوفر كدواء مركب بجرعة ثابتة مع ڤالسارتان) تستعمل لعلاج قصور وظيفة عضلة القلب طويل الأمد.</p><p dir="RTL">- ليناجلبتين، ساكساجلبتين، سيتاجلبتين، ڤيلداجلبتين و الأدوية الأخرى التي تنتمي لهذه المجموعة التي تعرف أيضا بالجلبتينات (تستعمل لعلاج داء السكري).</p><p dir="RTL">قد يزداد خطر الإصابة بالوذمة الوعائية إذا كنت من أصول ذوي البشرة السوداء و قد يكون هذا الدواء أقل فاعلية في خفض ضغط الدم مقارنة بالمرضى ذوي البشرة غير السوداء.</p><p dir="RTL"><strong><u>الوذمة</u></strong><strong><u> </u></strong><strong><u>الوعائية</u></strong></p><p dir="RTL">تم تسجيل حدوث الوذمة الوعائية (تفاعل تحسسي حاد مصحوب بتورم الوجه، الشفاه، اللسان، أو الحلق مع صعوبة في البلع أو التنفس) عند المرضى الذين تم علاجهم باستعمال مثبطات الإنزيم المحول للأنجيوتنسن، بما في ذلك بريندوبريل آرجنين/أملوديبين. قد يحدث هذا في أي وقت خلال العلاج. إذا عانيت من هذه الأعراض، يجب عليك التوقف عن تناول <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> و رؤية الطبيب فورا.</p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك حامل (أو من الممكن حصول الحمل).</p><p dir="RTL">لايوصى باستعمال <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> في المرحلة المبكرة من الحمل، ويجب عدم تناوله إذا كان عمر الحمل يزيد عن ثلاثة أشهر، حيث قد يسبب ضرر خطير للجنين إذا تم استعماله في هذه المرحلة.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong> <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص،</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الطاقم</strong><strong> </strong><strong>الطبي</strong><strong> </strong><strong>بما</strong><strong> </strong><strong>يلي</strong><strong>:</strong></p><p dir="RTL">إذا كنت ستخضع للتخدير العام و/أو عملية جراحية كبرى.</p><p dir="RTL">إذا عانيت مؤخرا من إسهال أو قيء.</p><p dir="RTL">إذا كنت ستخضع&nbsp; لعملية فصل البروتين الدهني منخفض الكثافة من الدم (هو إزالة الكوليستيرول من الدم عن طريق جهاز معين).</p><p dir="RTL">إذا كنت ستخضع لعلاج إزالة التحسس لتقليل تأثيرات التحسس للسعات النحل أو الدبور.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المراهقون</strong></p><p dir="RTL">لا يوصى باستعمال <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong> للأطفال و المراهقين.</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>تجنب</strong><strong> </strong><strong>استعمال</strong> <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong><strong> </strong><strong>بالتزامن</strong><strong> </strong><strong>مع</strong><strong>:</strong></p><p dir="RTL">الليثيوم (يستعمل لعلاج الهوس أو الاكتئاب).</p><p dir="RTL">إستراميوستين (يستعمل في علاج السرطان).</p><p dir="RTL">مدرات البول الحافظة للبوتاسيوم (ترايامتيرين، أميلوريد)، مكملات البوتاسيوم أو بدائل الأملاح المحتوية على البوتاسيوم، الأدوية الأخرى التي قد تزيد مستوى البوتاسيوم في الجسم) مثل، هيبارين، دواء يستعمل للوقاية من التجلطات؛ ترايميثوبريم و كوترايموكسازول الذي يعرف أيضا بترايميثوبريم/سلفاميثوكسازول لعلاج الالتهابات الناتجة عن البكتيريا).</p><p dir="RTL">الأدوية الحافظة للبوتاسيوم التي تستعمل لعلاج قصور وظيفة عضلة القلب: إيبليرينون وسبيرونولاكتون بجرعات تتراوح بين 12.5 ملغم و 50 ملغم في اليوم.</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>يتأثر</strong><strong> </strong><strong>العلاج</strong><strong> </strong><strong>باستعمال</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong><strong> </strong><strong>بالأدوية</strong><strong> </strong><strong>الأخرى</strong><strong>. </strong><strong>قد</strong><strong> </strong><strong>يحتاج</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>تغيير</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>و</strong><strong>/</strong><strong>أو</strong><strong> </strong><strong>اتخاذ</strong><strong> </strong><strong>احتياطات</strong><strong> </strong><strong>أخرى</strong><strong>. </strong><strong>تأكد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>إخبار</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>حيث</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تحتاج</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>إتخاذ</strong><strong> </strong><strong>احتياطات</strong><strong> </strong><strong>خاصة</strong><strong>:</strong></p><p dir="RTL">الأدوية الأخرى لعلاج ارتفاع ضغط الدم، بما في ذلك حاصرات مستقبلات أنجيوتنسن II، أليسيكرين أو مدرات البول (أدوية تزيد من كمية البول الذي تنتجه الكلى).</p><p dir="RTL">أدوية تستعمل غالبا لعلاج الإسهال (راسيكادوتريل) أو لتجنب رفض الأعضاء المزروعة (سيروليموس، إڤيروليموس، تيمسيروليموس و الأدوية الأخرى التي تنتمي إلى مجموعة تعرف بمثبطات هدف الثدييات من الراباميسين).</p><p dir="RTL">ساكوبيتريل/ڤالسارتان (يستعمل لعلاج قصور وظيفة عضلة القلب طويل الأمد).</p><p dir="RTL">الأدوية غير الستيرويدية المضادة للالتهاب (مثل، أيبوبروفين) لتخفيف الألم أو جرعات عالية من حمض أسيتيل ساليساليك، و هي مادة توجد في العديد من الأدوية تستعمل لتخفيف الألم و خفض درجة الحرارة، أيضا للوقاية من تجلط الدم.</p><p dir="RTL">الأدوية التي تستعمل لعلاج داء السكري (مثل، الإنسولين).</p><p dir="RTL">أدوية لعلاج الاضطرابات العقلية مثل الاكتئاب، القلق، الفصام ... و غيرها (مثل مضادات الاكتئاب ثلاثية الحلقة، مضادات الذهان، مضادات الاكتئاب التي تشبه الإيميبرامين، مهدئات الأعصاب القوية).</p><p dir="RTL">مثبطات المناعة (أدوية تستعمل لتقليل آلية دفاع الجسم) تستعمل لعلاج اضطرابات المناعة الذاتية أو بعد عمليات زرع الأعضاء (مثل سايكلوسبورين، تاكروليموس).</p><p dir="RTL">ترايميثوبريم و كوترايموكسازول (يستعمل لعلاج الالتهابات).</p><p dir="RTL">ألوبيورينول (يستعمل لعلاج النقرس).</p><p dir="RTL">بروكيناميد (يستعمل لعلاج عدم انتظام نبضات القلب).</p><p dir="RTL">الأدوية الموسعة للأوعية الدموية بما في ذلك النيترات (مستحضرات تعمل على توسيع الأوعية الدموية).</p><p dir="RTL">إيفيدرين، نورأدرينالين أو أدرينالين (الأدوية التي تستعمل لعلاج انخفاض ضغط الدم، الصدمة أو الربو).</p><p dir="RTL">باكلوفين أو دانترولين (عن طريق الحقن الوريدي البطيء) يستعمل كلاهما لعلاج تصلب العضلات في الأمراض مثل التصلب المتعدد؛ دانترولين يستعمل أيضا لعلاج ارتفاع درجة الحرارة الخبيث خلال عملية التخدير (تتضمن الأعراض ارتفاع درجة حرارة الجسم بشكل كبير و تصلب العضلات).</p><p dir="RTL">بعض المضادات الحيوية مثل ريفامبيسين، إيريثرومايسين، كلاريثرومايسين (لعلاج الالتهابات الناتجة عن البكتيريا).</p><p dir="RTL">هيبيريكوم بيرفوراتم (عشبة سانت جون، دواء عشبي يستعمل لعلاج الاكتئاب).</p><p dir="RTL">سيمڤاستاتين (دواء يستعمل لخفض مستوى الكوليستيرول).</p><p dir="RTL">أحد عوامل مضادات الصرع مثل كاربامازيبين، فينوباربيتال، فينيتوين، فوسفينيتوين، بريميدون.</p><p dir="RTL">إيتراكونازول، كيتوكونازول (أدوية تستعمل لعلاح الالتهابات الفطرية).</p><p dir="RTL">حاصرات ألفا التي تستعمل لعلاج تضخم البروستات مثل برازوسين، ألفوزوسين، دوكسازوسين، تامسولوسين، تيرازوسين.</p><p dir="RTL">أميفوستين (يستعمل للوقاية أو لتخفيف الآثار الجانبية الناتجة عن الأدوية الأخرى أو العلاج الإشعاعي التي يتم استعمالها لعلاج السرطان).</p><p dir="RTL">الستيرويدات القشرية (تستعمل لعلاج حالات مختلفة بما في ذلك الربو الحاد و التهاب المفاصل الروماتزمي).</p><p dir="RTL">أملاح الذهب، خصوصا التي تستعمل عن طريق الحقن الوريدي (تستعمل لعلاج أعراض التهاب المفاصل الروماتزمي).</p><p dir="RTL">ريتوناڤير، إنديناڤير، نيلفيناڤير (أيضا تعرف بمثبطات البروتياز تستعمل لعلاج ڤيروس نقص المناعة المكتسبة).</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong><sup> </sup></strong><strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الشراب</strong></p><p dir="RTL">يجب تناول <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong><sup>&nbsp; </sup></strong>قبل تناول الوجبة.</p><p dir="RTL">يجب عدم تناول عصير وفاكهة الجريب فروت من قبل الأشخاص الذين يتناولون <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong>.<sup> <strong>&nbsp;</strong></sup>وذلك لأن كلاهما قد يؤدي إلى زيادة مستويات المادة الفعالة أملوديبين في الدم، والذي قد يسبب زيادة غير متوقعة في تأثير <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong><sup>&nbsp; </sup></strong>الخافض لضغط الدم.</p><p dir="RTL"><strong>الحمل،</strong><strong> </strong><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الخصوبة</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء، إذا كنت حامل أو مرضعة، تعتقدين بأنك حامل أو تخططين للحمل.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك حامل (أو من الممكن حصول الحمل). سينصحك طبيبك عادة بالتوقف عن تناول <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> قبل حصول الحمل أو فور معرفتك بحصول الحمل وسينصحك بتناول دواء آخر بدل من <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong>. لا يوصى باستعمال <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> في المرحلة المبكرة من الحمل، ويجب عدم تناوله إذا كان عمر الحمل يزيد عن ثلاثة أشهر، حيث قد يسبب ضرر خطير على الجنين إذا تم استعماله بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">تبين أن أملوديبين يفرز في حليب الثدي بكميات صغيرة. أخبري الطبيب إذا كنت مرضعة أو على وشك البدء بالإرضاع. لا يوصى باستعمال <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> للأمهات المرضعات، و قد يقوم طبيبك باختيار علاج آخر إذا كنت ترغبين بالإرضاع، خصوصا إذا كان طفلك حديث الولادة، أو ولد قبل أوانه.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong><strong> </strong></p><p dir="RTL">قد يؤثر <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> على قدرتك على القيادة أو استخدام الآلات. إذا جعلتك الأقراص تشعر بالغثيان، الدوار، الضعف أو التعب، أو الصداع، تجنب القيادة أو استخدام الآلات واتصل مع طبيبك على الفور.</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong><strong> </strong><strong>على</strong><strong> </strong><strong>اللاكتوز</strong><strong> </strong></p><p dir="RTL">يحتوي <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong><strong> </strong>على اللاكتوز. إذا أخبرت من قبل الطبيب بأنك غير قادر على تحمل بعض السكريات، اتصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء<strong> </strong>تماما كما أخبرك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">تناول الأقراص مع شرب كأس من الماء، يفضل في نفس الوقت من كل يوم، في الصباح، قبل الوجبة. سيقرر طبيبك الجرعة الصحيحة لك. التي ستكون عادة قرص واحد في اليوم.</p><p dir="RTL">سيتم يتم وصف <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong><strong> </strong>عادة للمرضى الذين يتناولون بيريندوبريل و أملوديبين باستعمال أقراص منفصلة.</p><p dir="RTL"><strong>الاستعمال</strong><strong> </strong><strong>للأطفال</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المراهقين</strong></p><p dir="RTL">لا يوصى باستعماله للأطفال و المراهقين.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تناولت أقراص أكثر مما يجب، اتصل مع أقرب قسم للطوارئ و الحوادث أو أخبر طبيبك فورا. الأثر الأكثر احتمالا في حالة فرط الجرعة هو انخفاض ضغط الدم الذي قد يجعلك تشعر بالدوار أو الإغماء. إذا حدث هذا، قد يساعد الاستلقاء مع رفع الساقين.</p><p dir="RTL">قد تتجمع السوائل الزائدة في الرئتين (وذمة رئوية) مما يسبب قصر النفس الذي يظهر عادة خلال 24 &ndash; 48 ساعة أو أقل بعد تناوله.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong></p><p dir="RTL">من المهم تناول دوائك كل يوم كعلاج منتظم ليكون أكثر فاعلية. لكن، إذا نسيت تناول جرعة من <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong>، تناول الجرعة التالية في الوقت المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong></p><p dir="RTL">بما أن العلاج باستعمال <strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong><strong> </strong>يكون عادة طويل الأمد، يجب عليك مناقشة طبيبك قبل التوقف عن تناول الأقراص.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب <strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> آثار جانبية، على الرغم من عدم حصولها لدى الجميع.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية،</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>الدوائي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong><strong>وأخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورا</strong><strong>:</strong></p><p dir="RTL">أزيز تنفسي مفاجيء، ألم في الصدر، قصر النفس، أو صعوبة في التنفس.</p><p dir="RTL">تورم الجفون، الوجه أو الشفاه.</p><p dir="RTL">تورم اللسان و الحلق، الذي يسبب صعوبة شديدة في التنفس.</p><p dir="RTL">تفاعلات جلدية حادة بما في ذلك طفح جلدي شديد، شرى، احمرار الجلد في جميع أنحاء الجسم، حكة حادة، تنفط، تقشر و تورم الجلد، التهاب الأغشية المخاطية (متلازمة ستيفن &ndash; جونسون، تحلل نخري سام في البشرة) أو تفاعلات تحسسية أخرى.</p><p dir="RTL">شعور حاد بالدوار أو الإغماء.</p><p dir="RTL">نوبة قلبية، نبضات قلب سريعة غير معتادة أو غير طبيعية، أو ألم في الصدر.</p><p dir="RTL">التهاب البنكرياس الذي قد يسبب ألم حاد في البطن و الظهر مصحوب بالشعور بالمرض الشديد.</p><p dir="RTL"><strong>تم</strong><strong> </strong><strong>تسجيل</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الشائعة</strong><strong> </strong><strong>التالية</strong><strong>. </strong><strong>إذا</strong><strong> </strong><strong>سبب</strong><strong> </strong><strong>لك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>منها</strong><strong> </strong><strong>مشاكل</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>استمرت</strong><strong> </strong><strong>لأكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أسبوع،</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>عليك</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطبيب</strong><strong>.</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">وذمة (احتباس السوائل).</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">صداع، شعور بالدوار، شعور بالنعاس (خصوصا في بداية العلاج)، رنح، تنميل أو شعور بوخز خفيف في الأطراف، اضطرابات في الرؤية (بما في ذلك ازدواجية الرؤية)، طنين في الأذنين (شعور بإزعاج في الأذنين)، خفقان (الشعور بنبضات القلب)، احمرار الوجه، دوخة نتيجة انخفاض ضغط الدم، سعال، قصر النفس، شعور بالغثيان، قيء، ألم في البطن، اضطرابات في حاسة التذوق، عسر الهضم أو صعوبة في الهضم، تغير في حركة الأمعاء، إسهال، إمساك، تفاعلات تحسسية (مثل طفح جلدي، حكة)، تشنج العضلات، شعور بالتعب، شعور بالضعف، تورم الكاحل (وذمة طرفية).</p><p dir="RTL"><strong>تم</strong><strong> </strong><strong>تسجيل</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>تتضمن</strong><strong> </strong><strong>القائمة</strong><strong> </strong><strong>التالية</strong><strong>. </strong><strong>إذا</strong><strong> </strong><strong>ازدادت</strong><strong> </strong><strong>حدة</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>منها،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>لم</strong><strong> </strong><strong>تذكر</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة،</strong><strong> </strong><strong>الرجاء</strong><strong> </strong><strong>إخبار</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>.</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">تقلبات المزاج، قلق، اكتئاب، عدم القدرة على النوم، اضطرابات في النوم، ارتعاش، إغماء، فقدان الإحساس بالألم، نبضات القلب غير منتظمة، التهاب الأنف (انسداد أو سيلان الأنف)، تساقط الشعر، بقع حمراء على الجلد، تلون الجلد، ألم في الظهر، ألم في المفاصل، ألم في العضلات، ألم في الصدر، اضطراب في التبول، زيادة الحاجة إلى التبول في الليل، زيادة عدد مرات التبول، ألم، الشعور بالمرض، تشنج القصبات (ضيق في الصدر، أزيز تنفسي وقصر النفس)، جفاف الفم، وذمة وعائية (تتضمن الأعراض أزيز تنفسي، تورم الوجه أو اللسان)، تكون تجمعات من التنفطات على الجلد، مشاكل في الكلى، ضعف جنسي، زيادة التعرق، فرط الحمضات (نوع من خلايا الدم البيضاء)، الشعور بعدم الراحة أو تضخم الثدي عند الرجال، زيادة أو نقصان الوزن، تسارع نبضات القلب، التهاب الأوعية الدموية، تفاعلات تحسسية للضوء (زيادة تحسس الجلد لأشعة الشمس)، حمى، السقوط، تغيرات في قيم الفحوصات المخبرية: ارتفاع مستوى البوتاسيوم في الدم الذي يعود إلى وضعه الطبيعي عند التوقف عن العلاج، انخفاض مستوى الصوديوم، انخفاض مستوى السكر في الدم في حالة المرضى الذين يعانون من داء السكري، ارتفاع مستوى اليوريا، و ارتفاع مستوى الكرياتينين في الدم.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">قصور حاد في وظيفة الكلى، أعراض حالة تعرف بمتلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول: لون البول داكن، شعور بالغثيان أو قيء، تشنج العضلات، ارتباك و نوبات صرع، انخفاض أو عدم القدرة على التبول، ازدياد حالة الصدفية سوءا، تغيرات في قيم الفحوصات المخبرية: زيادة مستوى إنزيمات الكبد، ارتفاع مستوى البيليروبين في مصل الدم.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>نادرة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">اضطرابات قلبية وعائية (ذبحة، نوبة قلبية و سكتة دماغية)، التهاب الرئة الأيوزوني (هو مرض&nbsp; يتجمع فيه نوع معين من&nbsp;خلايا الدم البيضاء&nbsp;تسمى&nbsp;الكريات الحمضية&nbsp;&ldquo; الإيزونوفيلية&nbsp;&ldquo;) (نوع نادر من التهاب الرئة)، تورم الجفون، الوجه أو الشفاه، تورم اللسان و الحلق، الذي يسبب صعوبة شديدة في التنفس، تفاعلات جلدية حادة بما في ذلك طفح جلدي شديد، شرى، احمرار الجلد على كامل الجسم، حكة حادة، تنفط، تقشر و تورم الجلد، التهاب الأغشية المخاطية (متلازمة ستيفن- جونسون)، حمامي متعددة الأشكال (طفح جلدي الذي يبدأ عادة على شكل بقع حمراء مصحوبة بحكة على الوجه، الذراعين أو الساقين)، تحسس للضوء، تغير في قيم الدم مثل انخفاض عدد كريات الدم البيضاء و الحمراء، انخفاض الهيموجلوبين، انخفاض عدد الصفيحات الدموية، اضطرابات في الدم، التهاب البنكرياس الذي قد يسبب ألم حاد في البطن و الظهر مصحوب بالشعور بالمرض الشديد، اضطراب وظائف الكبد، التهاب الكبد، اصفرار الجلد (اليرقان)، ارتفاع مستوى إنزيمات الكبد التي قد تؤثر على بعض الفحوصات الطبية، انتفاخ البطن (التهاب المعدة)، اضطراب في الأعصاب الذي قد يسبب&nbsp; الشعور بالضعف، الشعور بوخز خفيف أو تنميل، زيادة توتر العضلات، تورم اللثة، فرط مستوى السكر في الدم.</p><p dir="RTL"><strong>التكرار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>معروف</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>البيانات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">ارتعاش، وضعية متصلبة، وجه يشبه القناع (وجه خالي من التعابير)، بطء الحركة و المشي بجر القدمين (المشي بسحب القدمين أو بدون رفعهما بالكامل عن الأرض)، مشي غير متوازن، تلون، تنميل و ألم في أصابع اليدين أو أصابع القدمين (ظاهرة رينود).</p><p dir="RTL">إذا عانيت من هذه الأعراض اتصل مع طبيبك في أقرب وقت.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الممرض</strong><strong>. </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong>&nbsp; </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل<strong> </strong>أقراص<strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong> <strong>بلص</strong> بعد تاريخ انتهاء الصلاحية المذكورعلى الملصق و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong> أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>برستوبريكس</strong><strong><sup>&reg; </sup></strong><strong>بلص</strong></p><p dir="RTL">المواد الفعالة هي بيريندوبريل آرجينين و أملوديبين (بيسايلات).</p><p dir="RTL">المكونات الأخرى هي ميكروكريستالين سيليلوز، جلايكولات نشا الصوديوم (نوع A)، سيليكا غروية لا مائية، ستيرات المغنيسوم، رذاذ اللاكتوز أحادي الهيدرات المجفف، لاكتوز أحادي الهيدرات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong><strong> 5 /5 </strong><strong>ملغم</strong><strong>: </strong>أقراص محدبة الوجهين، بيضاوية الشكل ذات لون أبيض مائل إلى الأصفر، ذات حواف مسطحة محفور على أحد الأوجه C22، معبأة في عبوات بولي إيثيلين عالي الكثافة ذات غطاء أبيض مقاوم للفتح من قبل الأطفال يحتوي على سيليكا مجففة (2 غم)، مع وجود دليل للكشف عن التلاعب، معده للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 قرص/ عبوة بولي إيثيلين عالي الكثافة.</p><p dir="RTL"><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong><strong> 10 /5 </strong><strong>ملغم</strong><strong>: </strong>أقراص محدبة الوجهين، مثلثة الشكل ذات لون أبيض مائل إلى الأصفر، ذات حواف مسطحة محفور على أحد الأوجه C27، معبأة في عبوات بولي إيثيلين ذات غطاء أبيض مقاوم للفتح من قبل الأطفال يحتوي على سيليكا مجففة</p><p dir="RTL">(2 غم)، مع وجود دليل للكشف عن التلاعب، معده للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 قرص/ عبوة بولي إيثيلين عالي الكثافة.</p><p dir="RTL"><strong>برستوبريكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>بلص</strong><strong> 10 /10 </strong><strong>ملغم</strong><strong>: </strong>أقراص محدبة الوجهين، دائرية الشكل ذات لون أبيض مائل إلى الأصفر، ذات حواف مسطحة محفور على أحد الأوجه 23C، معبأة في عبوات بولي إيثيلين عالي الكثافة ذات غطاء أبيض مقاوم للفتح من قبل الأطفال يحتوي على سيليكا مجففة (2 غم)، مع وجود دليل للكشف عن التلاعب، معده للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 قرص/ عبوة بولي إيثيلين عالي الكثافة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>العربي</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">&nbsp;فاكس: 00966126358138</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 42512 &ndash; جدة&nbsp; 21551</p><p dir="RTL">بريد الكتروني:&nbsp; MD.admin@Axantia.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p>هذه النشرة لا تحتوي على جميع المعلومات عن المستحضر. إذا كان لديك أية أسئلة أو لم تكن متأكدا من أي شيء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/ 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prestoprix® Plus 5/5 mg tablets.
Prestoprix® Plus 10/5 mg tablets. 
Prestoprix® Plus 10/10 mg tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prestoprix® Plus 5/5 mg tablets: Each tablet contains 5 mg Perindopril arginine and 5 mg amlodipine.
Prestoprix® Plus 10/5 mg tablets: Each tablet contains 10 mg Perindopril arginine and 5 mg amlodipine.
Prestoprix® Plus 10/10 mg tablets: Each tablet contains 10 mg Perindopril arginine and 10 mg amlodipine.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. 

Prestoprix® Plus 5/5 mg: White to off white oval biconvex beveled edge tablet engraved with C22 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, 28 mm, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use.
Prestoprix® Plus 10/5 mg: White to off white Triangle biconvex beveled edge tablet engraved with C27 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, 28 mm, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use. 
Prestoprix® Plus 10/10 mg: White to off white Round biconvex beveled edge tablet engraved with C32 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, 28 mm, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Prestoprix<sup>&reg; </sup>Plus</strong> is indicated as substitution therapy for treatment of essential hypertension and/or stable coronary artery disease, in patients already controlled with perindopril and amlodipine given concurrently at the same dose level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Oral route.</p><p>One tablet per day as a single dose, preferably to be taken in the morning and before a meal.</p><p>The fixed dose combination is not suitable for initial therapy.</p><p>If a change of posology is required, the dose of <strong>Prestoprix<sup>&reg; </sup>Plus</strong> could be modified or individual titration with free combination may be considered.</p><p><strong><u>Special populations </u></strong></p><p><strong>Renal impairment and elderly (see sections 4.4 and 5.2) </strong></p><p>Elimination of perindopril at is decreased in the elderly and in patients with renal failure. Therefore, the usual medical follow-up will include frequent monitoring of creatinine and potassium.</p><p><strong>Prestoprix<sup>&reg; </sup>Plus</strong> can be administered in patients with Clcr &ge; 60ml/min, and is not suitable for patients with Clcr &lt; 60ml/min. In these patients, an individual dose titration with the monocomponents is recommended.</p><p>Amlodipine used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p><strong>Hepatic impairment (see sections 4.4 and 5.2) </strong></p><p>Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2). To find the optimal starting dose and maintenance dose of patients with hepatic impairment, the patients should be individually titrated using the free combination of amlodipine and perindopril. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.</p><p><strong>Paediatric population </strong></p><p><strong>Prestoprix<sup>&reg; </sup>Plus</strong> should not be used in children and adolescents as the efficacy and tolerability of perindopril and amlodipine, in combination, have not been established in children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Linked to perindopril: 
•	Hypersensitivity to the active substance or to any other ACE inhibitor.
•	History of angioedema associated with previous ACE inhibitor therapy.
•	Hereditary or idiopathic angioedema.
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
•	Concomitant use of Prestoprix® Plus with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) (see sections 4.5 and 5.1). 
•	Concomitant use with sacubitril/valsartan therapy. Prestoprix® Plus must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see sections 4.4 and 4.5). 
•	Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5). 
•	Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see section 4.4). 
Linked to amlodipine: 
•	Severe hypotension.
•	Hypersensitivity to the active substance or to dihydropyridines derivatives.
•	Shock, including cardiogenic shock.
•	Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis). 
•	Haemodynamically unstable heart failure after acute myocardial infarction. 
Linked to Prestoprix® Plus: 
•	All contraindications related to each monocomponent, as listed above, should apply also to the fixed combination of Prestoprix® Plus. 
•	Hypersensitivity to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All warnings related to each monocomponent, as listed below, should apply also to the fixed combination of <strong>Prestoprix<sup>&reg; </sup>Plus</strong>.</p><p><strong><u>Linked to perindopril </u></strong></p><p><strong>Special warnings </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hypersensitivity/Angioedema: </strong></p><p>Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/or larynx has been reported rarely in patients treated with ACE inhibitors, including perindopril (see section 4.8). This may occur at any time during therapy. In such cases, <strong>Prestoprix<sup>&reg; </sup>Plus</strong> should promptly be discontinued and appropriate monitoring should be initiated and continued until complete resolution of symptoms has occurred. In those instances where swelling was confined to the face and lips the condition generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p><p>Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p>Intestinal angioedema has been reported rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain (see section 4.8).</p><p>The combination of perindopril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. If treatment with sacubitril/valsartan is stopped, perindopril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5). Concomitant use of ACE inhibitors with NEP inhibitors (e.g. racecadotril), mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) in a patient already taking an ACE inhibitor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis: </strong></p><p>Rarely, patients receiving ACE inhibitors during low-density lipoprotein (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anaphylactoid reactions during desensitisation: </strong></p><p>Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have experienced anaphylactoid reactions. In the same patients, these reactions have been avoided when the ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Neutropenia/Agranulocytosis/Thrombocytopenia/Anaemia: </strong></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely.</p><p>Perindopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If perindopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g. sore throat, fever).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renovascular hypertension: </strong></p><p>There is an increased risk of hypotension and renal insufficiency when patient with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors (see section 4.3). Treatment with diuretics may be a contributory factor. Loss of renal function may occur with only minor changes in serum creatinine even in patients with unilateral renal artery stenosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS): </strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Primary aldosteronism: </strong></p><p>Patients with primary hyperaldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of this product is not recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pregnancy: </strong></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitors is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><strong>Precautions for use </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hypotension: </strong></p><p>ACE inhibitors may cause a fall in blood pressure. Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients and is more likely to occur in patients who have been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or who have severe renin-dependent hypertension (see sections 4.5 and 4.8). In patients at high risk of symptomatic hypotension, blood pressure, renal function and serum potassium should be monitored closely during treatment with <strong>Prestoprix<sup>&reg; </sup>Plus</strong>.</p><p>Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Aortic and mitral valve stenosis / hypertrophic cardiomyopathy:</strong></p><p>As with other ACE inhibitors, perindopril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal impairment: </strong></p><p>In cases of renal impairment (creatinine clearance &lt; 60 ml/min) an individual dose titration with the monocomponents is recommended (see section 4.2).</p><p>Routine monitoring of potassium and creatinine are part of normal medical practice for patients with renal impairment (see section 4.8).</p><p>In some patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, who have been treated with ACE inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when perindopril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic failure: </strong></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see section 4.8).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Race: </strong></p><p>ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>As with other ACE inhibitors, perindopril may be less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cough: </strong></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Surgery/Anaesthesia: </strong></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, <strong>Prestoprix<sup>&reg; </sup>Plus</strong> may block angiotensin II formation secondary to compensatory renin release. The treatment should be discontinued one day prior to the surgery. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hyperkaliemia: </strong></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril, ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. Risk factors for the development of hyperkalemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, and concomitant use of potassium-sparing diuretics (e.g. spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparin, co-trimoxazole also known as trimethoprim/sulfamethoxazole) and especially aldosterone antagonists or angiotensin-receptor blockers. The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalemia can cause serious, sometimes fatal arrhythmias. Potassium-sparing diuretics and angiotensin-receptor blockers should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored. If concomitant use of perindopril and any of the above mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diabetic patients:</strong></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see section 4.5).</p><p><strong><u>Linked to amlodipine: </u></strong></p><p><strong>Precautions for use</strong></p><p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cardiac failure:</strong></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic impairment:</strong></p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elderly:</strong></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal failure:</strong></p><p>Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p><strong>Linked to </strong><strong>Prestoprix<sup>&reg; </sup>Plus</strong></p><p>All warnings related to each monocomponent, as listed above, should apply also to the fixed combination of <strong>Prestoprix<sup>&reg; </sup>Plus</strong>.</p><p><strong>Precautions for use</strong></p><p><strong>Excipients:</strong></p><p>Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the total lactase deficiency should not take this medicinal product.</p><p>Interactions;</p><p>The concomitant use of <strong>Prestoprix<sup>&reg; </sup>Plus</strong> with lithium, potassium-sparing drugs or potassium supplements, or dantrolene is not recommended (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Linked to perindopril </u></strong></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><strong>Drugs increasing the risk of angioedema </strong></p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4). Sacubitril/valsartan must not be started until 36 hours after taking the last dose of perindopril therapy. Perindopril therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.4).</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk for angioedema (see section 4.4).</p><p><strong>Drugs inducing hyperkalaemia: </strong></p><p>Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with <strong>Prestoprix<sup>&reg; </sup>Plus</strong>. Some drugs or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren, potassium salts, potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. The combination of these drugs increases the risk of hyperkalaemia. Therefore, the combination of <strong>Prestoprix<sup>&reg; </sup>Plus</strong> with the above-mentioned drugs is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium.</p><p><strong>Concomitant use contra-indicated (see section 4.3): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Aliskiren: </strong></p><p>In diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Extracorporeal treatments: </strong></p><p>Extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitril membranes) and low density lipoprotein apheresis with dextran sulphate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p><strong>Concomitant use not recommended (see section 4.4): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Aliskiren: </strong></p><p>In patients other than diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Concomitant therapy with ACE inhibitor and angiotensin-receptor blocker: </strong></p><p>It has been reported in the literature that in patients with established atherosclerotic disease, heart failure, or with diabetes with end organ damage, concomitant therapy with ACE inhibitor and angiotensin-receptor blocker is associated with a higher frequency of hypotension, syncope, hyperkalaemia, and worsening renal function (including acute renal failure) as compared to use of a single renin-angiotensin-aldosterone system agent. Dual blockade (e.g, by combining an ACE-inhibitor with an angiotensin II receptor antagonist) should be limited to individually defined cases with close monitoring of renal function, potassium levels, and blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Estramustine:</strong></p><p>Risk of increased adverse effects such as angioneurotic oedema (angioedema).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Potassium-sparing diuretics (e.g. triamterene, amiloride...), potassium salts: </strong></p><p>Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkalaemic effects).</p><p>The the combination of perindopril with the above-mentioned drugs is not recommended (see section 4.4). If concomitant use is nonetheless indicated, they should be used with caution and with frequent monitoring of serum potassium. For use of spironolactone in heart failure, see below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lithium: </strong></p><p>Reversible increases in serum lithium concentrations and toxicity (severe neurotoxicity) have been reported during concurrent use of ACE inhibitors. The combination of perindopril with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</p><p><strong>Concomitant use which requires special care: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Antidiabetic agents (insulins, oral hypoglycaemic agents): </strong></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Non-potassium-sparing diuretics: </strong></p><p>Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor. The possibility of hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake prior to initiating therapy with low and progressive doses of perindopril.</p><p>In arterial hypertension, when prior diuretic therapy can have caused salt/volume depletion, either the diuretic must be discontinued before initiating the ACE inhibitor, in which case a non-potassium-sparing diuretic can be thereafter reintroduced or the ACE inhibitor must be initiated with a low dosage and progressively increased.</p><p>In diuretic-treated congestive heart failure, the ACE inhibitor should be initiated at a very low dosage, possibly after reducing the dosage of the associated non-potassium-sparing diuretic.</p><p>In all cases, renal function (creatinine levels) must be monitored during the first few weeks of ACE inhibitor therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Potassium-sparing diuretics (eplerenone, spironolactone): </strong></p><p>With eplerenone or spironolactone at doses between 12.5 mg to 50 mg by day and with low doses of ACE inhibitors:</p><p>In the treatment of class II-IV heart failure (NYHA) with an ejection fraction &lt;40%, and previously treated with ACE inhibitors and loop diuretics, risk of hyperkalaemia, potentially lethal, especially in case of non-observance of the prescription recommendations on this combination.</p><p>Before initiating the combination, check the absence of hyperkalaemia and renal impairment.</p><p>A close monitoring of the kalaemia and creatininemia is recommended in the first month of the treatment once a week at the beginning and, monthly thereafter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid &ge; 3 g/day: </strong></p><p>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><strong>Concomitant use which requires some care: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sympathomimetics: </strong></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gold: </strong></p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including perindopril.</p><p><strong><u>Linked to amlodipine </u></strong></p><p><strong>Concomitant use not recommended: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dantrolene (infusion):</strong></p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><strong>Concomitant use which requires special care: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CYP3A4 inducers:</strong></p><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CYP3A4 inhibitors:</strong></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co administered with clarithromycin.</p><p><strong>Concomitant use to be taken into consideration: </strong></p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tacrolimus:</strong></p><p>There is a risk of increased tacrolimus blood levels when co administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mechanistic Target of Rapamycin (mTOR) Inhibitors </strong></p><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ciclosporine: </strong></p><p>No drug interaction studies have been conducted with ciclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of ciclosporine were observed. Consideration should be given for monitoring ciclosporine levels in renal transplant patients on amlodipine, and ciclosporine dose reductions should be made as necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Simvastatin: </strong></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Others combinations: </strong></p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin.</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p><strong><u>Linked to </u></strong><strong><u>Prestoprix<sup>&reg; </sup>Plus</u></strong><strong><u>: </u></strong></p><p><strong>Concomitant use which requires special care: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Baclofen: </strong></p><p>Increased antihypertensive effect. Monitor blood pressure and adapt antihypertensive dosage if necessary.</p><p><strong>Concomitant use to be taken into consideration: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Antihypertensive agents (such as beta-blockers) and vasodilatators: </strong></p><p>Concomitant use of these agents may increase the hypotensive effects of perindopril and amlodipine. Concomitant use with nitroglycerine and other nitrates or other vasodilatators, may further reduce blood pressure and therefore should be considered with caution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Corticosteroids, tetracosactide:</strong></p><p>Reduction in antihypertensive effect (salt and water retention due to corticosteroids).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Alpha-blockers (prazosin, alfuzosin, doxazosin, tamsulosin, terazosin):</strong></p><p>Increased antihypertensive effect and increased risk of orthostatic hypotension.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Amifostine:</strong></p><p>May potentiate the antihypertensive effect of amlodipine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tricyclic antidepressants/antipsychotics/anaesthetics:</strong></p><p>Increased antihypertensive effect and increased risk of orthostatic hypotension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the effects of the individual components in this combination product on pregnancy and lactation:</p><p><strong>Prestoprix<sup>&reg; </sup>Plus</strong> is not recommended during the first trimester of pregnancy. <strong>Prestoprix<sup>&reg; </sup>Plus</strong> is contraindicated during the second and third trimesters of pregnancy.</p><p><strong>Prestoprix<sup>&reg; </sup>Plus</strong> is not recommended during lactation. A decision should therefore be made whether to discontinue nursing or to discontinue <strong>Prestoprix<sup>&reg; </sup>Plus</strong> taking account the importance of this therapy for the mother.</p><p><strong>Pregnancy: </strong></p><p><strong><u>Linked to perindopril </u></strong></p><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><strong><u>Linked to amlodipine </u></strong></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p><strong>Breast-feeding: </strong></p><p><strong><u>Linked to perindopril </u></strong></p><p>Because no information is available regarding the use of perindopril during breastfeeding, perindopril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><strong><u>Linked to amlodipine </u></strong></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3 &ndash; 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.</p><p><strong>Fertility: </strong></p><p><strong><u>Linked to perindopril </u></strong></p><p>There was no effect on reproductive performance or fertility.</p><p><strong><u>Linked to amlodipine</u></strong></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of <strong>Prestoprix<sup>&reg; </sup>Plus</strong> on the ability to drive and use machines have been performed. Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients suffer from dizziness, headache, fatigue, weariness or nausea, the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of safety profile </strong></p><p>The most commonly reported adverse reactions with perindopril and amlodipine given separately are: oedema, somnolence, dizziness, headache (especially at the beginning of the treatment), dysgeusia, paraesthesia, visual impairment (including diplopia), tinnitus, vertigo, palpitations, flushing, hypotension (and effects related to hypotension), dyspnoea, cough, abdominal pain, nausea, vomiting, dyspepsia, change of bowel habit, diarrheoa, constipation, prurit, rash, exanthema, joint swelling (ankle swelling), muscle spasms, fatigue, asthenia.</p><p><strong>b. Tabulated list of adverse reactions: </strong></p><p>The following undesirable effects have been observed during clinical trials and/or post-marketing use with perindopril or amlodipine given separately and ranked under the MedDRA classification by body system and under the following frequency:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1000 to &lt;1/100); rare (&ge;1/10000 to &lt;1/1000); very rare (&lt;1/10000); not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Undesirable Effects</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td><td style="vertical-align:top"><p><strong>Perindopril</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Rhinitis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Blood and the lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia/neutropenia (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Agranulocytosis or pancytopenia</p><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia in patients with a congenital deficiency of G-6PDH (see section 4.4)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorder</strong></p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>Hypoglycaemia (see sections 4.4 and 4.5)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia, reversible on discontinuation (see section 4.4)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Mood altered (including Anxiety)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorder</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="12" style="vertical-align:top"><p><strong>Nervous System disorders</strong></p></td><td style="vertical-align:top"><p>Somnolence (especially at the beginning of the treatment)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness (especially at the beginning of the treatment)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache (especially at the beginning of the treatment)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy peripheral</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Cerebrovascular accident possibly secondary to excessive hypotension in high-risk patients (see section 4.4)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Extrapyramidal disorder (extrapyramidal syndrome)</p></td><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris (see section 4.4)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction, possibly secondary to excessive hypotension in high risk patients (see section 4.4)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare*</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension (and effects related to hypotension)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td><p>Raynaud&#39;s phenomenon</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Not Known</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Respiratory, &nbsp;&nbsp;Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Eosinophilic pneumonia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p><strong>Gastro-intestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Change of bowel habit</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Hepato-biliary Disorders</strong></p></td><td style="vertical-align:top"><p>Hepatitis, jaundice</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis either cytolytic or cholestatic (see section 4.4)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic enzymes increased (mostly consistent with cholestasis)</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="16" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>Quincke&rsquo;s oedema</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema of face, extremities, lips, mucous membranes, tongue, glottis and/or larynx (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiform</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Skin discolouration</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Prurit</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash, exanthema</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria (see section 4.4)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Photosentivity reactions</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Pemphigoid</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Psoriasis aggravation</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson Syndrome</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative dermatitis</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Musculoskeletal And Connective Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>Joint swelling (ankle swelling)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>Micturition disorder, nocturia, pollakiuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Anuria/Oliguria</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Reproductive System and Breast Disorders</strong></p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecomastia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p><strong>General Disorders and Administration Site Condition</strong></p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Weight increased, weight decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Blood bilirubin increase</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic enzyme increase</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased and haematocrit decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>Fall</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr></tbody></table><p>* Frequency calculated from clinical trials for adverse events detected from spontaneous report</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect (s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdosage with <strong>Prestoprix<sup>&reg; </sup>Plus</strong> in humans.</p><p>For amlodipine, experience with intentional overdose in humans is limited.</p><p><strong>Symptoms:</strong></p><p>Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48 hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p><strong>Treatment:</strong></p><p>Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p><p>For perindopril, limited data are available for overdosage in humans. Symptoms associated with the overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough.</p><p>The recommended treatment of overdosage is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. Periondopril can be removed from the systemic circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for treatment-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> ACE inhibitors and calcium channel blockers, <strong>ATC code:</strong> C09BB04.</p><p><strong>Perindopril: </strong></p><p><strong><u>Mechanism of action </u></strong></p><p>Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin and is partially responsible for certain of their side effects (e.g. cough).</p><p>Perindopril acts through its active metabolite, perindoprilat. The other metabolites show no inhibition of ACE activity in vitro.</p><p><strong>Clinical efficacy and safety </strong></p><p><strong>Hypertension: </strong></p><p>Perindopril is active in all grades of hypertension: mild, moderate, severe; a reduction in systolic and diastolic blood pressures in both supine and standing positions is observed.</p><p>Perindopril reduces peripheral vascular resistance, leading to blood pressure reduction. As a consequence, peripheral blood flow increases, with no effect on heart rate.</p><p>Renal blood flow increases as a rule, while the glomerular filtration rate (GFR) is usually unchanged.</p><p>The antihypertensive activity is maximal between 4 and 6 hours after a single dose and is sustained for at least 24 hours: trough effects are about 87-100 % of peak effects.</p><p>The decrease in blood pressure occurs rapidly. In responding patients, normalisation is achieved within a month and persists without the occurrence of tachyphylaxis.</p><p>Discontinuation of treatment does not lead to a rebound effect.</p><p>Perindopril reduces left ventricular hypertrophy.</p><p>In man, perindopril has been confirmed to demonstrate vasodilatory properties. It improves large artery elasticity and decreases the media:lumen ratio of small arteries.</p><p><strong>Stable coronary artery disease: </strong></p><p>The EUROPA study was a multicentre, international, randomised, double-blind, placebo-controlled clinical trial lasting 4 years.</p><p>Twelve thousand two hundred and eighteen (12218) patients aged over 18 were randomised to 8 mg perindopril tert-butylamine (equivalent to 10 mg perindopril arginine) (n=6110) or placebo (n=6108).</p><p>The trial population had evidence of coronary artery disease with no evidence of clinical signs of heart failure. Overall, 90% of the patients had a previous myocardial infarction and/or a previous coronary revascularisation. Most of the patients received the study medication on top of conventional therapy including platelet inhibitors, lipid lowering agents and beta-blockers.</p><p>The main efficacy criterion was the composite of cardiovascular mortality, non fatal myocardial infarction and/or cardiac arrest with successful resuscitation. The treatment with 8 mg perindopril tert-butylamine (equivalent to 10 mg perindopril arginine) once daily resulted in a significant absolute reduction in the primary endpoint of 1.9% (relative risk reduction of 20%, 95%CI [9.4; 28.6] &ndash; p&lt;0.001).</p><p>In patients with a history of myocardial infarction and/or revascularisation, an absolute reduction of 2.2% corresponding to a RRR of 22.4% (95%CI [12.0; 31.6] &ndash; p&lt;0.001) in the primary endpoint was observed by comparison to placebo.</p><p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) clinical trial data: </strong></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed.</p><p>Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><strong>Amlodipine: </strong></p><p><strong>Mechanism of action </strong></p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>- Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</p><p>- The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p><strong>Clinical efficacy and safety </strong></p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><strong>Coronary artery disease (CAD): </strong></p><p>The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multi-center, randomized, double- blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Table 1. Incidence of significant clinical outcomes for CAMELOT</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular event rates, No. (%)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Amlodipine vs. placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Outcomes </strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine </strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p></td><td style="vertical-align:top"><p><strong>Enalapril </strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio (95% CI) </strong></p></td><td style="vertical-align:top"><p><strong>P Value </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Primary Endpoint </u></strong></p><p>Adverse cardiovascular events</p></td><td style="vertical-align:top"><p>110 (16.6)</p></td><td style="vertical-align:top"><p>151 (23.1)</p></td><td style="vertical-align:top"><p>136 (20.2)</p></td><td style="vertical-align:top"><p>0.69 (0.54-0.88)</p></td><td style="vertical-align:top"><p>.003</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Individual Components </u></strong></p><p>Coronary revascularization</p><p>&nbsp;</p><p>Hospitalization for angina</p><p>&nbsp;</p><p>Nonfatal MI</p><p>&nbsp;</p><p>Stroke or TIA</p><p>&nbsp;</p><p>Cardiovascular death</p><p>&nbsp;</p><p>Hospitalization for CHF</p><p>&nbsp;</p><p>Resuscitated cardiac arrest</p><p>&nbsp;</p><p>New-onset peripheral vascular disease</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>78 (11.8)</p><p>&nbsp;</p><p>51 (7.7)</p><p>&nbsp;</p><p>&nbsp;</p><p>14 (2.1)</p><p>&nbsp;</p><p>6 (0.9)</p><p>&nbsp;</p><p>&nbsp;</p><p>5 (0.8)</p><p>&nbsp;</p><p>3 (0.5)</p><p>&nbsp;</p><p>&nbsp;</p><p>0</p><p>&nbsp;</p><p>&nbsp;</p><p>5 (0.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>103</p><p>(15.7)</p><p>&nbsp;</p><p>84 (12.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>19 (2.9)</p><p>&nbsp;</p><p>12 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>2 (0.3)</p><p>&nbsp;</p><p>5 (0.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>4 (0.6)</p><p>&nbsp;</p><p>&nbsp;</p><p>2 (0.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>95 (14.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>86 (12.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>11 (1.6)</p><p>&nbsp;</p><p>8 (1.2)</p><p>&nbsp;</p><p>&nbsp;</p><p>5 (0.7)</p><p>&nbsp;</p><p>4 (0.6)</p><p>&nbsp;</p><p>&nbsp;</p><p>1 (0.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>8 (1.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>0.73 (0.54-0.98)</p><p>&nbsp;</p><p>0.58 (0.41-0.82)</p><p>&nbsp;</p><p>0.73 (0.37-1.46)</p><p>0.50 (0.19-1.32)</p><p>&nbsp;</p><p>2.46 (0.48-12.7)</p><p>0.59 (0.14-2.47)</p><p>&nbsp;</p><p>NA</p><p>&nbsp;</p><p>&nbsp;</p><p>2.6 (0.50-13.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>.03</p><p>&nbsp;</p><p>&nbsp;</p><p>.002</p><p>&nbsp;</p><p>&nbsp;</p><p>.37</p><p>&nbsp;</p><p>.15</p><p>&nbsp;</p><p>&nbsp;</p><p>.27</p><p>&nbsp;</p><p>.46</p><p>&nbsp;</p><p>&nbsp;</p><p>.04</p><p>&nbsp;</p><p>&nbsp;</p><p>.24</p></td></tr></tbody></table><p>Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.</p><p><strong>Heart failure: </strong></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>In a follow-up, long term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema.</p><p><strong>Treatment to prevent heart attack trial (ALLHAT): </strong></p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke &gt; 6 months prior to enrollment or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 (95% CI(0.90-1.07) p=0.65). Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs 7.7%, RR 1.38, (95% CI [1.25-1.52] p&lt;0.001)).</p><p>However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy, RR 0.96 (95% CI [0.89-1.02] p=0.20).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The rate and extent of absorption of perindopril and amlodipine from <strong>Prestoprix<sup>&reg; </sup>Plus</strong> are not significantly different, respectively, from the rate and extent of absorption of perindopril and amlodipine from individual tablet formulations.</p><p><strong><u>Perindopril: </u></strong></p><p><strong>Absorption </strong></p><p>After oral administration, the absorption of perindopril is rapid and the peak concentration is achieved within 1 hour. The plasma half-life of perindopril is equal to 1 hour.</p><p>Perindopril is a prodrug. Twenty seven percent of the administered perindopril dose reaches the bloodstream as the active metabolite perindopril at. In addition to active perindopril at, perindopril yields five metabolites, all inactive. The peak plasma concentration of perindopril at is achieved within 3 to 4 hours.</p><p>As ingestion of food decreases conversion to perindopril at, hence bioavailability, perindopril arginine should be administered orally in a single daily dose in the morning before a meal.</p><p>It has been demonstrated a linear relationship between the dose of perindopril and its plasma exposure.</p><p><strong>Distribution </strong></p><p>The volume of distribution is approximately 0.2 l/kg for unbound perindopril at. Protein binding of perindopril at to plasma proteins is 20%, principally to angiotensin converting enzyme, but is concentration-dependent.</p><p><strong>Elimination </strong></p><p>Perindopril at is eliminated in the urine and the terminal half-life of the unbound fraction is approximately 17 hours, resulting in steady-state within 4 days.</p><p>Elderly, Heart Failure, Renal Failure</p><p>Elimination of perindopril at is decreased in the elderly, and also in patients with heart or renal failure (see section 4.2). Therefore, the usual medical follow-up will include frequent monitoring of creatinine and potassium.</p><p><strong>Hepatic impairment </strong></p><p>Dialysis clearance of perindopril at is equal to 70 ml/min.</p><p>Perindopril kinetics are modified in patients with cirrhosis: hepatic clearance of the parent molecule is reduced by half. However, the quantity of perindopril at formed is not reduced and therefore no dosage adjustment is required (see sections 4.2 and 4.4).</p><p><strong><u>Amlodipine: </u></strong></p><p><strong>Absorption, distribution, plasma protein binding </strong></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg. In vitro studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><strong>Biotransformation/Elimination </strong></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><strong>Elderly </strong></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p><strong>Hepatic impairement: </strong></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Perindopril: </u></strong></p><p>In the chronic oral toxicity studies (rats and monkeys), the target organ is the kidney, with reversible damage.</p><p>No mutagenicity has been observed in in vitro or in vivo studies.</p><p>Reproduction toxicology studies (rats, mice, rabbits and monkeys) showed no sign of embryotoxicity or teratogenicity. However, angiotensin converting enzyme inhibitors, as a class, have been shown to induce adverse effects on late fetal development, resulting in fetal death and congenital effects in rodents and rabbits: renal lesions and an increase in peri- and postnatal mortality have been observed. Fertility was not impaired either in male or in female rats.</p><p>No carcinogenicity has been observed in long term studies in rats and mice.</p><p><strong><u>Amlodipine: </u></strong></p><p><strong>Reproductive toxicology </strong></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><strong>Impairment of fertility </strong></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p><strong>Carcinogenesis, mutagenesis </strong></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>* Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose, sodium starch glycolate (Type A), colloidal anhydrous silica, magnesium stearate, lactose monohydrate spray dried,&nbsp;lactose monohydrate agglomerated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Prestoprix<sup>&reg; </sup>Plus<sup> </sup>5/5 mg</strong>: White to off white oval biconvex beveled edge tablet engraved with C22 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, 28 mm, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use.</p><p><strong>Pack size: </strong>30 Tablets / HDPE Bottle.</p><p><strong>Prestoprix<sup>&reg; </sup>Plus<sup> </sup>10/5 mg: </strong>White to off white Triangle biconvex beveled edge tablet engraved with C27 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, 28 mm, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use.</p><p><strong>Pack size: </strong>30 Tablet / HDPE Bottle.</p><p><strong>Prestoprix<sup>&reg; </sup>Plus<sup> </sup>10/10 mg: </strong>White to off white Round biconvex beveled edge tablet engraved with C32 on one side and plain on other side, presented in HDPE Bottle and closed with Cap, 28 mm, White CRC, Tamper Evident with Mounted Silica Gel Desiccant Canister (2 gm), intended for oral use.</p><p><strong>Pack size: </strong>30 Tablets / HDPE Bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Med City Pharma-KSA.
Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551
E-mail: MD.admin@Axantia.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>